Short Interest in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Declines By 77.6%

Posted by Geri Gentry on May 13th, 2026

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Get Free Report) saw a significant decrease in short interest in the month of April. As of April 30th, there was short interest totaling 112,316 shares, a decrease of 77.6% from the April 15th total of 502,390 shares. Approximately 2.6% of the company’s shares are short sold. Based on an average daily volume of 169,623 shares, the short-interest ratio is currently 0.7 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a report on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Check Out Our Latest Stock Report on Galmed Pharmaceuticals

Hedge Funds Weigh In On Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Citadel Advisors LLC bought a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 50,492 shares of the biopharmaceutical company’s stock, valued at approximately $71,000. Citadel Advisors LLC owned approximately 3.05% of Galmed Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 76.14% of the stock is currently owned by institutional investors.

Galmed Pharmaceuticals Price Performance

GLMD stock traded up $0.01 during trading on Wednesday, reaching $0.60. The company had a trading volume of 29,608 shares, compared to its average volume of 165,306. Galmed Pharmaceuticals has a 52 week low of $0.41 and a 52 week high of $2.34. The company has a market cap of $3.26 million, a P/E ratio of -0.48 and a beta of 0.62. The business has a 50 day moving average of $0.62 and a 200 day moving average of $0.80.

Galmed Pharmaceuticals Company Profile

(Get Free Report)

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.